We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Patients implanted with affected devices should expect to be contacted directly for a follow-up assessment, if required.
More than 40 people hospitalised following suspected use of unlicensed botulinum toxin products.
As with any medicine, the MHRA will keep the safety of gepotidacin under close review.
As with any medicine, the MHRA will keep the safety of zuranolone under close review.
The pilot will help sponsors prepare for a new substantial modifications process under upcoming regulations, with responses delivered within 14 days.
Parents and caregivers who have purchased Nutrition Ignition Kids Magnesium Glycinate Gummies should stop giving them to children and safely dispose of any remaining product. It is recommended that advice be sought from a he…
As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about zuranolone.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about 3 growth hormone agonists.
Letter from the Advisory Council on the Misuse of Drugs (ACMD) to the Minister for Policing and Crime Prevention, about the consideration of ganaxolone.
WHO recognition affirms MHRA’s commitment to regulatory excellence, innovation and global collaboration
The microscopic bacteria living in women’s bodies could be a powerful tool for personalised, non-invasive treatment and earlier diagnosis.
Under a joint information sharing agreement, pharmaceutical companies will be invited to register early with the MHRA and NICE to allow parallel decision making over licencing and value.
New measures to crack down on cowboy cosmetic procedures will be introduced by the government.
New jobs to strengthen innovation, safety and smarter regulation across the UK health and life sciences sector.
Due to risk of infection, non-sterile alcohol-free wipes are not appropriate for the treatment of injuries, wounds or on broken skin, nor for cleaning of intravenous lines.
Statement of Policy Intent sets out initial thinking on a new Early Access service to help patients benefit sooner from innovative medical devices that address unmet clinical needs.
The approval is supported by a study involving 453 adults with advanced platinum-resistant cancers of the ovary, fallopian tubes and the peritoneum that were FRα positive
New genetic therapy approved for SOD1-ALS brings targeted treatment option to patients in the UK
A new regional centre to promote Yellow Card reporting has been launched in Belfast today.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).